Copaiba oil

Other Names

AceiteAceite de paloAceite de zarazaAmaceyBalsam CopaibaBálsamo de CopaybaBásamo de CopaybaBaume de copahuCabimaCabimbaCabimoCabismoCapiviCobeniCopahuCopaíbaCopaibaCopaiba BalsamCopaiba officinalisCopaiba Oil-ResinCopaiba OleoresinCopaiba-verdadeiraCopaibeiraCopaibeura-de-MinasCopaibura-de-MinasCopaier officinalCopaíferaCopaifera jacquiniiCopaifera langsdorffiiCopaifera multijugaCopaifera nitidaCopaifera officinalisCopaifera pauperaCopaifera reticulataCopaifera sellowiiCopaiperaCopaivaCopaívaCopaiva officinalisCopalCopalliCopaubaCopaúvaCopayerCupa-ybaCupayCupaybaDiesel treeHuile de copahuHuile rouge de copayerJesuit's BalsamKerosene treeKupa'iwaKupa'uKupa'yMal-dos-sete-diasMatidisguateMatisihuatiPalo de aceitePalo-de-bálsamoPau-de-oleoPau-de-óleoTacamaca

Synopsis

Copaiba Oil: A Comprehensive Reference

1. Identity: Botanical Names, Natural Source, and Preparations

1.1 Taxonomy and Botanical Source

Copaiba trees belong to the genus Copaifera, family Fabaceae, and subfamily Caesalpinoideae. Copaiba is an oleoresin obtained from the trunk of several pinnate-leaved South American leguminous trees (genus Copaifera). The species of Copaifera with a higher incidence in the Amazon region are Copaifera officinalis, Copaifera reticulata, and Copaifera multijuga Hayne. These are among the most pharmacologically studied species, although the genus encompasses numerous other species distributed across the Neotropics.

The main country of origin for the oleoresin and essential oil is Brazil, in particular the Amazon region, but Copaifera species distribution is wide across South America as well as West Africa. Today, Brazil produces approximately 95 percent of this oil-resin, exporting more than 500 tons each year.

1.2 What is Copaiba Oil?

Oleoresins present high viscosity and are liquid when just exudated from the trunks of trees. The oleoresin exudated from copaibas, known as copaiba oil, is obtained in amounts from 1 mL to 60 L. The thick, transparent exudate varies in color from light gold to dark brown, depending on the ratio of resin to essential oil.

The name "copaiba" originates from an indigenous Amazonian language (Tupi), cupa-yba, to denote "reservoir/vessel" with reference to its store of oleoresin in the trunk.

1.3 Extraction and Preparation Forms

The oleoresin of these trees is extracted through tapping, and the oleoresin is used therapeutically in its raw state or distilled to yield copaiba essential oil. The balsam may be steam distilled to give copaiba oil, a colorless to light yellow liquid with the characteristic odor of the balsam and an aromatic, slightly bitter, pungent taste. The fractions may be termed as volatile fraction (VF), which contains exclusively sesquiterpenes, and nonvolatile fraction (NVF), which is composed exclusively of diterpene acids.

Commercial forms include: the raw crude oleoresin (also called copaiba balsam or oil-resin), the steam-distilled essential oil, encapsulated softgel supplements for oral ingestion, topical creams and gels (including silicone-based scar gels), and dental compounded formulations. Copaifera trees play a vital role as an alternative remedy in the Amazon region of Brazil, and phytotherapeutic and cosmetic products using copaiba oil have found their way not only into the Brazilian market but also to international markets.

1.4 Quality and Adulteration Concerns

Despite the known chemical differences between the copaiba oils from different Copaifera species, copaiba oils are commonly commercialized without botanical identification. Product adulteration with soybean oil has been clearly detected, with each individual triglyceride in soybean oil being unambiguously identified using combined GC/MS and SFC/MS analytical techniques.

2. Traditional and Historical Use

2.1 Indigenous and Pre-Colonial Use

The oleoresin of Copaifera trees has been widely used as a traditional medicine in Neotropical regions for thousands of years and remains a popular treatment for a variety of ailments. Its medicinal use was described as early as 1534 by early European chroniclers during the invasion of the New World, when they observed its use by native populations for the treatment of wounds.

Oleoresin extracted from copaiba (Copaifera spp.: Leguminosae) trees is a popular traditional medicine in Amazonia. The traditional uses of copaiba oleoresin in the Brazilian Amazon include wound and ulcer healing, antimicrobial and anti-inflammatory properties for skin diseases, as well as relief of rheumatic diseases. Traditionally, it was used as an ointment for wounds and bruises, and ingested to treat internal ailments like respiratory and urinary tract issues.

2.2 Regional Ethnobotanical Variations

In Panama, the Yaviza people mix the resin with honey and give it to newborns to impart knowledge and ward off hexes. Within the Peruvian Amazon near Iquitos, it is also used as an insect repellent. The copaiba oil is used in the Amazon's traditional medicine, especially as an anti-inflammatory ingredient, in ulcer healing, scarring, and for leishmaniasis.

2.3 European Adoption and Historical Commerce

Originally considered in Europe as a panacea, and later as the anti-gonorrhoea remedy by excellence, Copahu balsam was forgotten after the discovery of penicillin. Use of this oleoresin is now so widespread that copaiba is the most popularly known and exploited medicinal plant in Brazil.

The balsam and its oil are also used as fixatives in soap perfumes and fragrances. Copaiba is also used in making varnishes and lacquers.

3. Key Constituents and Active Compounds

3.1 Overview of Chemical Composition

The main constituents found in copaiba oils are sesquiterpenes (volatile fraction) and diterpenes (resinous fraction), which can vary qualitatively and quantitatively between species of the Copaifera genus and in relation to biotic and abiotic factors.

The copaiba resins are generally composed of a volatile oil made up largely of sesquiterpene hydrocarbons, such as β-caryophyllene, α-copaene, β-elemene, α-humulene, and germacrene D. In addition, the oleoresin is also made up of several biologically active diterpene acids, including copalic acid, kaurenoic acid, alepterolic acid, and polyalthic acid.

3.2 Sesquiterpene Fraction (Volatile)

The main chemical constituent of copaiba oil is β-caryophyllene, which can be found in various essential oils. The chemical profile of copaiba oil might be slightly different from one species to another, but in general the main constituents are β-caryophyllene, α-humulene, α-copaene, α-bergamotene, δ-cadinene, and β-bisabolol.

In studies using GC/MS and multivariate analysis, β-caryophyllene and caryophyllene oxide have been identified as the main sesquiterpene components in Copaifera multijuga oil. There is a prevalence of sesquiterpenes in all the oils studied.

3.3 Diterpene Fraction (Resinous)

Some copaiba oils contain diterpene acids, such as copalic acid, clorechinic acid, and hardwickiic acid. The diterpene acids reside primarily in the non-volatile resinous fraction. Copaiba is also the primary source of copalic acid.

3.4 Chemical Variability

Several factors might cause chemical composition variation in copaiba oil, such as seasonal and climatic characteristics of the environment, soil type and composition, rainfall index, and species genetics.

4. Mechanisms of Action

4.1 β-Caryophyllene and the CB2 Receptor

The most extensively characterized mechanism involves β-caryophyllene (BCP) and the endocannabinoid system. The cutaneous endocannabinoid system (ECS), comprising cannabinoid receptors, endocannabinoids, and their metabolic enzymes, regulates inflammation, pruritus, barrier integrity, and tissue repair; cannabinoid receptor type 2 (CB2) has emerged as a particularly relevant target. β-Caryophyllene (BCP), a dietary sesquiterpene and highly selective CB2 agonist with favorable safety and pharmacokinetic attributes, has attracted attention as a promising topical candidate.

CB2 receptors are enriched on peripheral immune cells, keratinocytes, fibroblasts, sebocytes, and small-diameter sensory fibers, while their expression in the central nervous system (CNS) remains minimal. This peripheral bias enables selective CB2 agonists to exert anti-inflammatory and antipruritic effects without the psychotropic risks associated with CB1 activation.

β-Caryophyllene is a ligand of the cannabinoid receptor 2 (CB2); its activation has been associated with decreasing pain, a major signal of inflammatory response, and enhancing reepithelization.

4.2 Downstream Inflammatory Pathway Modulation

BCP penetrates the stratum corneum, suppresses NF-κB/MAPK and IL-4/TSLP pathways, enhances Nrf2-driven antioxidant defenses, and accelerates re-epithelialization and collagen remodeling.

CB2 signaling modulates mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK1/2), p38 MAPK, and c-Jun N-terminal kinase (JNK), and converges on nuclear factor kappa B (NF-κB), reducing the expression of cyclooxygenase-2 (COX-2), TNF-α, IL-1β, and IL-6.

4.3 Role of Additional Sesquiterpenes

The predominant sesquiterpene forms in copaiba oleoresin are β-Caryophyllene (bactericidal and anti-inflammatory), β-Bisabolene (anti-inflammatory), and α-Humulene (anti-inflammatory)—present in several essential oils.

4.4 Diterpene Acid Targets

Molecular docking has been carried out with Copaifera diterpenoids on cancer molecular targets, including androgen receptor, aromatase, cyclin-dependent kinases 2, 4, and 6, cyclooxygenase-2, DNA methyltransferases, epidermal growth factor receptor, estrogen receptors α and β, NF-κB, phosphatidylinositol-4,5-bisphosphate 3-kinase, topoisomerases I and IIα, and vascular endothelial growth factor receptor. These are computational (in silico) findings, and most have not yet been validated in clinical trials.

β-Caryophyllene (BCP) is a cannabinoid receptor 2 (CB2) agonist that tempers inflammation. An interaction between the CB2 receptor and peroxisome proliferator-activated receptor gamma (PPAR-γ) has been suggested, and PPAR-γ activation exerts anti-arthritic effects.

5. Scientific Evidence by Area of Use

5.1 Overview of the Evidence Base

Only 3 out of 6 clinical trials found in a 2023 comprehensive scientometric review originated from the medical field. These trials have a considerably higher certainty of evidence than in vitro and in vivo studies; however, a low number of clinical trials have been published overall. The majority of available evidence derives from animal models and cell-based (in vitro) studies. The sections below characterize evidence by area, noting where human clinical data exist and where evidence is limited to preclinical models.

5.2 Inflammation

Preclinical evidence: In animal studies, healthy and arthritic Holtzman rats received 215 and 430 mg/kg of BCP orally once a day for 18 days. Both doses of BCP reduced adjuvant-induced paw edema, swollen lymph nodes, and the number of circulating and articular leukocytes. Furthermore, the 430 mg/kg dose abolished increases in protein carbonyl groups and myeloperoxidase activity in the liver and plasma of arthritic rats. At both doses, the increased levels of reactive oxygen species and reduced glutathione in the arthritic liver were restored. These beneficial actions of BCP were to the same extent as those reported for C. reticulata oleoresin, suggesting BCP is possibly responsible for the anti-inflammatory and antioxidant actions of the copaiba oil.

Human evidence (arthritis, 2018): Thirty-six participants with rheumatoid arthritis, osteoarthritis, and/or chronic inflammation received the AromaTouch Hand Technique® (ATHT) with either a 50/50 preparation of Deep Blue® and Copaiba oil or a coconut oil placebo twice daily for 5 consecutive days. Changes in maximum flexion in finger and thumb joints, items from the Arthritis Hand Function Test, and hand pain scores were evaluated. Participants treated with the essential oil preparation required significantly less time to complete dexterity tasks and showed about a 50% decrease in pain scores, increased finger strength, and significantly increased angle of maximum flexion compared to the placebo group. Limitation: The active preparation was a mixture of copaiba with another product (Deep Blue), making it impossible to isolate the contribution of copaiba oil alone.

5.3 Wound Healing and Tissue Repair

Preclinical evidence: The oil-resin activity of C. langsdorffii was evaluated in an incision wound model in rats, and the contraction of excised wounds was observed in addition to measuring the tensile strength in wound healing. Topical application of oleoresin accelerated wound contraction, indicating a beneficial effect of the oil-resin of C. langsdorffii in wound healing, thus justifying its traditional use for the treatment of wounds.

Hematological and biochemical analyses revealed no significant alterations attributable to copaiba oil treatment in rat wound models. Histopathological evaluation of the heart, liver, and kidneys showed no evidence of tissue damage or morphological changes. These findings support the safety of topical copaiba oil, indicating it promotes wound healing without inducing systemic toxicity or hematological disturbances in rats.

Systematic review (oral cavity, 2021): Of five studies reviewed in a systematic review focused on oral wound healing, two reported beneficial wound healing effects, such as early reduction in the wound area and greater immature bone formation in the mandibles of the animal, and two reported beneficial anti-inflammatory effects, such as reduced acute inflammatory reaction and more advanced tissue repair stage. All five included studies were animal models; no human clinical trials of wound healing in the oral cavity were available at the time of the review.

5.4 Dermatology: Acne Vulgaris

Human clinical trial (2012): There was a highly significant decrease in the surface affected with acne in the areas treated with the 1.0% copaiba essential oil preparation (F = 86.494, p = 0.000, r = 0.834; r² = 0.695) over 21 days of treatment. This research evaluated the qualitative and quantitative composition of copaiba essential oil from the oil-resin and tested its effects after incorporation in a gel applied in volunteers with acne, in a double-blind, placebo-controlled clinical trial. The essential oil was extracted by steam distillation and purified by freezing to remove residual water. This is among the more methodologically robust human studies available, though the sample size and duration were limited.

5.5 Dermatology: Scar Reduction

Human clinical trial (2021): A prospective, randomized, double-blind, placebo-controlled trial involving 42 patients evaluated the efficacy of a novel silicone-based gel containing copaiba oil (Copaderm) for prevention and/or reduction in the appearance of different types of abnormal scars. This was the first clinical trial to demonstrate the effectiveness of topical copaiba oil in silicone-based gel for the prevention and improvement in the appearance of various scar types, including hypertrophic, acne, and keloid scars. During the 84-day comparison, participants were instructed to apply copaiba oil in silicone-based gel or a placebo gel on their scars. The results demonstrated that the application of copaiba oil in silicone-based gel twice per day achieved beneficial improvement in scar appearance after 84 days when compared with a placebo gel.

The application of copaiba oil in silicone-based gel twice per day achieved beneficial improvement in appearance of new scars after 84 days when compared with a placebo gel. Characteristics of color, contour, distortion, and texture of the scars showed significant score reductions (−0.72, −0.5, −0.83, and −0.83, respectively) from baseline to 84 days. Limitation: The gel formulation includes silicone, which independently has scar-reducing properties, making it difficult to fully attribute outcomes to copaiba oil alone.

5.6 Antimicrobial Activity

In vitro studies: Copaiba oil demonstrated antibacterial activity against Staphylococcus aureus, with a minimum inhibitory concentration (MIC) of 0.3125 mg/mL and a minimum bactericidal concentration (MBC) of 0.3125 mg/mL in broth microdilution testing. Even low concentrations of copaiba oil effectively inhibited Staphylococcus aureus growth, supporting its potential use as a promising adjuvant in compounded topical formulations for wound and scar healing.

A time-kill assay conducted with oleoresin concentrations between 50 and 100 mg/mL showed bactericidal activity against Fusobacterium nucleatum after 4 h, Prevotella nigrescens after 6 h, Porphyromonas gingivalis and Lactobacillus casei after 12 h, and Streptococcus mutans after 18 h.

Chromatographic analysis identified caryophyllene (60.89%), germacrene D (19.40%), and humulene (7.12%) as major compounds, and the pure copaiba extract demonstrated activity against the pathogens Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecalis. However, copaiba oleoresin in concentrations utilized to treat cutaneous wounds presented no bactericidal effects against prevalent microorganisms in wound infections in one study using wound-treatment concentrations, highlighting dose-dependence and the gap between laboratory and clinical concentrations.

Evidence strength: Antimicrobial activity is well-characterized in vitro. No controlled human clinical trials specifically testing antimicrobial outcomes in human infections have been identified.

5.7 Antiparasitic / Antileishmanial Activity

Preclinical evidence: Diterpene-rich copaiba oils showed antipromastigote activity against Leishmania amazonensis. Sesquiterpene-rich oils and isolated β-caryophyllene presented a dose-dependent activity against intracellular amastigotes, with IC50s of 2.9 µg/mL, 2.3 µg/mL, and 1.3 µg/mL (6.4 µM), respectively.

The copaiba oil and isolated terpenes have antiparasitic activity, more promising in the amastigote form of L. amazonensis. This activity is probably related to changes in the cell membrane and mitochondria. In summary, copaiba oil is promising as a leishmanicidal agent. All current evidence remains preclinical; no human trials for leishmaniasis treatment using copaiba oil have been completed.

5.8 Neuroprotection

Preclinical evidence only: Animal research cited in phytochemical reviews references neuroprotective effects of copaiba oil-resin following excitotoxic injury to motor cortex, including reduced neutrophil recruitment and microglial activation. Anti-inflammatory effects arise from modulation of cytokine cascades and inhibition of pro-inflammatory enzymes, while antioxidant mechanisms support tissue repair and re-epithelialization in wound-healing models. No human clinical trials on neuroprotection have been identified in the peer-reviewed literature.

5.9 Anxiety / Mood

A randomized controlled trial (Zhang et al., 2022, published in Evidence-Based Complementary and Alternative Medicine) investigated the effect of copaiba oil odor on anxiety relief in adults under mental workload. This study explored aromatherapy (inhalation) as the route. Evidence in this domain is limited to this single trial and further research is needed to establish reliability and reproducibility.

5.10 Anticancer Activity

The chemosensitivity of cancer cells caused by BCP results in a reduction in the amount of chemotherapy administered. This combined activity has contributed to reduced treatment costs, fewer side effects, and less damage to the patients' organs. In addition, BCP serves as a cytotoxic agent inducing cell cycle arrest, apoptosis, and inflammation through production of reactive oxygen species (ROS). It also serves as a glioblastoma suppressor, allowing paclitaxel to diffuse across the membrane more easily, thus enhancing the anticancer effects of chemotherapeutic drugs. All anticancer evidence is currently confined to cell lines and animal models; no human clinical trial data are available.

5.11 Oral / Dental Health

The number of studies in the oral science field has been constantly growing due to the potential antimicrobial effect of copaiba, especially against oral pathogens. 17 out of 25 studies on the use of copaiba in the oral cavity and orofacial region were published between 2010 and 2020. Studies have examined effects on periodontal bacteria, root canal sealers, and oral wound healing, predominantly in preclinical or in vitro models. In cell-based studies, BCP reversed increases in the inflammatory cytokines TNF-α, IL-1β, IL-6, and IL-17A induced by LPS, with upstream signals identified in augmented expression of NF-κB and STAT-3.

6. Body Systems Associated with Copaiba Oil

Integumentary system (skin): Wound healing, scar reduction, acne treatment, anti-inflammatory and barrier-restorative topical activity.
Musculoskeletal system: Anti-inflammatory and analgesic effects in arthritis and rheumatic conditions (preclinical and limited clinical evidence).
Immune system: Copaifera oleoresins exert an activating profile in human monocytes without affecting cell viability, and diterpene or sesquiterpene acids are thought to be involved in their mechanisms of action.
Oral cavity: Antimicrobial activity against oral pathogens, wound healing after dental procedures (predominantly preclinical).
Nervous system (pain pathways): CB2-mediated analgesic activity documented in animal models; limited clinical data from the arthritis hand massage study.
Hepatobiliary system: Investigated both for hepatoprotective and potential hepatotoxic properties (discussed under Safety).
Respiratory / cardiovascular system: BCP is one of the most important components of copaiba oil, popularly used in Brazil for respiratory and cardiovascular illnesses. Nano-capsules of copaiba oil were shown to attenuate monocrotaline-induced pulmonary arterial hypertension in rats by counteracting oxidative stress and inflammation, and by improving cardiac function. (Preclinical only.)

7. Dosage Forms and Reported Dosages

No universally accepted therapeutic dose has been established for copaiba oil in humans. Dosages reported in specific studies are summarized below as stated in the source literature:

Topical gel for acne (clinical trial, 2012): A 1.0% copaiba essential oil gel preparation applied for 21 days produced significant reductions in acne surface area.
Topical silicone-based gel for scars (clinical trial, 2021): Participants applied copaiba oil in silicone-based gel or a placebo gel on their scars, with the active gel applied twice per day for 84 days.
Hand massage (arthritis clinical trial, 2018): Participants received treatments with a 50/50 preparation of Deep Blue® and Copaiba oil or a coconut oil placebo twice daily for 5 consecutive days.
Oral dose in animal acute toxicity testing: In an acute toxicity test, a 2000 mg/kg dose of the oleoresin was administered via an intragastric tube (gavage) at 10 mL/kg.
Oral dose in animal subacute toxicity testing: To evaluate subacute toxicity, animals received oral doses of 25, 50, and 100 mg/kg for 28 days.
Estimated safe oral dose for females of reproductive age (extrapolated from animal NOAELs): For females of reproductive age, the estimated safe dose for oral administration is 5 mg/kg/day.
Estimated safe exposure level based on animal NOAEL: The estimated safe exposure level for humans, based on the non-observed adverse effect level (NOAEL) found in guinea pigs for maternal and developmental toxicity, was 500 mg/kg/day.

8. Safety Considerations and Interactions

8.1 General Toxicological Profile

Copaiba oils can be administered as a local healing agent, as well as an anti-hemorrhoidal, purgative, anticarcinogenic, anti-inflammatory, antimicrobial, and anesthetic agent, though sufficient evidence of its efficacy and pharmacological safety are still required.

An extensive review of in vitro, in vivo, and in silico toxicity studies for copaiba oils and their constituents has been conducted as a way of systematizing knowledge and allowing for the inference of toxic effects of some terpenes. Copaiba oils are often consumed on a large scale for medicinal purposes, and the review highlights where investigations are still needed for their use to be considered safe.

8.2 Hepatic Effects

The hepatic effects of copaiba oil appear complex and context-dependent. Some studies have demonstrated a hepatoprotective effect of copaiba oil and concluded that there was no hepatic toxicity. However, copaiba oil administered prophylactically for seven days and therapeutically could reduce liver damage caused by paracetamol similarly to N-Acetyl-Cysteine; however, when treated with copaiba therapeutically, it showed increases in bilirubin, affecting the indirect fraction. This signals that context of use (prophylactic versus therapeutic) may matter for hepatic outcomes.

8.3 Reproductive Toxicology

The effects on reproductive performance following the oral administration of C. multijuga oleoresin in male Wistar rats at doses of 200, 500, and 2500 mg/kg/day were evaluated during eight weeks, with no signs of toxicity. Treated rats were mated with untreated females and no stillborns or fetal malformations were found, indicating absence of externally visible teratogenic effects. The results confirmed that oral treatment with this copaiba oil at the concentrations evaluated did not induce toxic effects on the male reproductive system, on the animals' fertility, nor on the development of their offspring. These are animal data and cannot be directly extrapolated to humans.

8.4 Cytotoxicity at Higher Concentrations

Cell viability and cytotoxicity assays showed that the lowest concentrations of oleoresin used presented similar results to the control group, while the higher concentrations tested significantly decreased cell viability and increased cytotoxicity. The main components found in copaiba oleoresin were sesquiterpenes, and the low tested concentrations were not cytotoxic. This dose-dependent cytotoxicity has implications for both therapeutic use and safety margins.

8.5 β-Caryophyllene Oxide and Stability

BCP's volatility and autoxidation to β-caryophyllene oxide (BCPO) necessitate stability-by-design strategies using antioxidants, low-oxygen processing, and protective packaging. The oxidation product BCPO may have different biological activity and safety profiles compared to the parent compound.

8.6 Human Evidence Gaps

Human evidence, limited to BCP-rich botanicals such as Copaifera oleoresins, suggests benefits for scars, wounds, and acne but lacks compound-specific validation. Dose-defined, oxidation-controlled clinical trials of purified BCP are warranted to establish its potential as a steroid-sparing topical therapy.

8.7 Product Adulteration as a Safety Concern

Product adulteration with soybean oil has been clearly detected, with each individual triglyceride in soybean oil being unambiguously identified in commercial samples. Adulteration affects both efficacy and safety assessments, particularly for individuals with soy allergies or those relying on the product for specific therapeutic constituents.

8.8 Species Identification Concern

Despite known chemical differences between the copaiba oils from different Copaifera species, copaiba oils are commonly commercialized without botanical identification. Because diterpene acid composition varies across species, and some diterpenes have demonstrated acute toxicity in rodent models, the lack of species identification creates uncertainty about safety profiles of commercial products.

8.9 Kaurenoic Acid Toxicity

Among the diterpene constituents, kaurenoic acid has moderate solubility in water and high gastrointestinal absorption. In another study using ADMET PredictorTM software, kaurenoic acid presented acute toxicity in rats. This is an in silico finding, but it reinforces the importance of species-specific composition data in safety evaluations.

References

Health Conditions

Health conditions that Copaiba oil may help support.

No conditions available.

Body Systems

Body systems that Copaiba oil may help support.

No body systems available.